The Indian multinational pharmaceutical company, Cipla, is a well-known name in the healthcare industry. The company has been making waves in the stock market, with analysts predicting a bright future for Cipla’s share price target in the next few years.
With a focus on innovation and providing affordable healthcare solutions, many investors are considering Cipla as a good auto stock to buy. One such example of Cipla’s innovative spirit is its recent launch of a point-of-care testing device, which has the potential to revolutionize the way people receive medical tests.
This article will explore the potential of Cipla’s share price target from 2024 to 2030, examining the factors that could impact its growth and making predictions for the future.
More About Cipla
Cipla Limited is a leading Indian multinational pharmaceutical company headquartered in Mumbai, founded in 1935 by Khwaja Abdul Hamied. Under the leadership of CEO Umang Vohra, it is the 2nd largest pharmaceutical player in India and a leader in respiratory and urology therapies. With a 7.5% market share in the South African private market, it continues to grow faster than the market average. Additionally, Cipla is the 2nd largest Indian exporter in emerging markets, reporting a strong revenue of ₹22,753 crores INR (US$2.8 billion) in FY23.
Cipla Q3 FY24 Financial Highlights
- Consolidated Net Profit: ₹1,056 crore, a 32% YoY increase.
- Total Revenue from Operations: ₹6,603 crore, with a marginal dip from the previous quarter.
- Total Expenses: Increased by 8.78% to ₹5,119.81 crore.
- Total Income: Rose significantly by 14.58% to ₹6,788.44 crore.
- Segment Revenue (Pharmaceutical): Contributed ₹6,365.06 crore, marking a 12.61% YoY increase.
- EBITDA: Surged 24.2% YoY to ₹1,748 crore.
- North American Business: Achieved highest-ever quarterly revenue of $230 million, an 18% YoY growth.
- South Africa Business: Recorded a robust 15% YoY revenue increase in local currency terms.
- Equity Share Capital: Increased to ₹161.47 crore.
- Management Statement: Umang Vohra, MD and Global CEO highlighted a 14% YoY topline growth with strong EBITDA margins at 26.3%.
- Overall Performance: Strong performance in North American and South African businesses drove positive financial results
You can buy Cipla shares from the following trading platforms:
➤ Zerodha
➤ Upstox
➤ Groww
➤ AngelOne
➤ ICICIDirect
| When | Maximum Price | Minimum Price |
| April 2024 | 1,576.80 | 1,371.13 |
| May 2024 | 1,553.50 | 1,350.87 |
| June 2024 | 1,609.42 | 1,399.50 |
| July 2024 | 1,593.33 | 1,385.50 |
| August 2024 | 1,657.06 | 1,440.92 |
| September 2024 | 1,723.34 | 1,498.56 |
| October 2024 | 1,689.55 | 1,469.18 |
| November 2024 | 1,740.24 | 1,513.25 |
| December 2024 | 1,783.75 | 1,551.08 |
In April 2024, Cipla’s share price is expected to range between ₹1,371.13 and ₹1,576.80.
With a market cap of ₹1,17,907 Cr. and a current price of ₹1,460 (as of April 4, 2024), the company anticipates steady growth throughout the year.
| When | Maximum Price | Minimum Price |
| January 2025 | 1,819.42 | 1,399.55 |
| February 2025 | 1,866.07 | 1,435.44 |
| March 2025 | 1,938.85 | 1,491.42 |
| April 2025 | 1,900.83 | 1,462.18 |
| May 2025 | 1,845.47 | 1,419.59 |
| June 2025 | 1,928.52 | 1,483.47 |
| July 2025 | 1,890.70 | 1,454.39 |
| August 2025 | 1,949.18 | 1,499.37 |
| September 2025 | 2,017.40 | 1,551.84 |
| October 2025 | 2,069.85 | 1,592.19 |
| November 2025 | 2,121.60 | 1,632.00 |
| December 2025 | 2,174.64 | 1,672.80 |
In 2025, Cipla’s shares are forecasted to see a gradual upward trend, with prices ranging from ₹1,399.55 to ₹2,174.64 throughout the year. This suggests a promising trajectory for investors in the pharmaceutical company.
| When | Maximum Price | Minimum Price |
| January 2026 | 2,239.88 | 1,722.98 |
| February 2026 | 2,297.31 | 1,767.16 |
| March 2026 | 2,386.90 | 1,836.08 |
| April 2026 | 2,340.10 | 1,800.08 |
| May 2026 | 2,271.94 | 1,747.65 |
| June 2026 | 2,374.18 | 1,826.29 |
| July 2026 | 2,327.63 | 1,790.48 |
| August 2026 | 2,399.62 | 1,845.86 |
| September 2026 | 2,483.60 | 1,910.46 |
| October 2026 | 2,548.18 | 1,960.14 |
| November 2026 | 2,611.88 | 2,009.14 |
| December 2026 | 2,677.18 | 2,059.37 |
| When | Maximum Price | Minimum Price |
| January 2027 | 2,730.72 | 2,100.55 |
| February 2027 | 2,800.74 | 2,154.42 |
| March 2027 | 2,909.97 | 2,238.44 |
| April 2027 | 2,852.91 | 2,194.55 |
| May 2027 | 2,769.82 | 2,130.63 |
| June 2027 | 2,894.46 | 2,226.51 |
| July 2027 | 2,837.70 | 2,182.85 |
| August 2027 | 2,925.47 | 2,250.36 |
| September 2027 | 3,027.86 | 2,329.12 |
| October 2027 | 3,106.58 | 2,389.68 |
| November 2027 | 3,184.25 | 2,449.42 |
| December 2027 | 3,263.85 | 2,510.66 |
| When | Maximum Price | Minimum Price |
| January 2028 | 3,329.13 | 2,560.87 |
| February 2028 | 3,414.49 | 2,626.53 |
| March 2028 | 3,547.66 | 2,728.97 |
| April 2028 | 3,478.10 | 2,675.46 |
| May 2028 | 3,376.79 | 2,597.53 |
| June 2028 | 3,528.75 | 2,714.42 |
| July 2028 | 3,459.56 | 2,661.20 |
| August 2028 | 3,566.55 | 2,743.50 |
| September 2028 | 3,691.38 | 2,839.53 |
| October 2028 | 3,787.36 | 2,913.35 |
| November 2028 | 3,882.04 | 2,986.19 |
| December 2028 | 3,979.09 | 3,060.84 |
| When | Maximum Price | Minimum Price |
| January 2029 | 4,058.68 | 3,122.06 |
| February 2029 | 4,162.75 | 3,202.11 |
| March 2029 | 4,325.09 | 3,326.99 |
| April 2029 | 4,240.29 | 3,261.76 |
| May 2029 | 4,116.78 | 3,166.76 |
| June 2029 | 4,302.04 | 3,309.26 |
| July 2029 | 4,217.68 | 3,244.37 |
| August 2029 | 4,348.13 | 3,344.71 |
| September 2029 | 4,500.31 | 3,461.78 |
| October 2029 | 4,617.32 | 3,551.79 |
| November 2029 | 4,732.75 | 3,640.58 |
| December 2029 | 4,851.07 | 3,731.59 |
| When | Maximum Price | Minimum Price |
| January 2030 | 4,948.09 | 3,806.23 |
| February 2030 | 5,074.97 | 3,903.82 |
| March 2030 | 5,272.89 | 4,056.07 |
| April 2030 | 5,169.50 | 3,976.54 |
| May 2030 | 5,018.93 | 3,860.72 |
| June 2030 | 5,244.79 | 4,034.45 |
| July 2030 | 5,141.95 | 3,955.34 |
| August 2030 | 5,300.98 | 4,077.67 |
| September 2030 | 5,486.51 | 4,220.39 |
| October 2030 | 5,629.16 | 4,330.12 |
| November 2030 | 5,769.89 | 4,438.38 |
| December 2030 | 5,914.14 | 4,549.34 |
Financial Condition of Cipla: Last 5 years
| Year | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM |
|---|---|---|---|---|---|---|
| Sales (in Crore INR) |
16,362 | 17,132 | 19,160 | 21,763 | 22,753 | 23,707 |
| Expenses (in Crore INR) |
13,265 | 13,926 | 14,907 | 17,211 | 17,726 | 18,329 |
| Operating Profit (in Crore INR) |
3,097 | 3,206 | 4,252 | 4,553 | 5,027 | 5,378 |
| OPM % | 19% | 19% | 22% | 21% | 22% | 23% |
| Other Income (in Crore INR) |
477 | 344 | 266 | 99 | 293 | 326 |
| Interest (in Crore INR) |
168 | 197 | 161 | 106 | 110 | 108 |
| Depreciation (in Crore INR) |
1,326 | 1,175 | 1,068 | 1,052 | 1,172 | 1,157 |
| Profit before tax (in Crore INR) |
2,079 | 2,178 | 3,290 | 3,493 | 4,038 | 4,438 |
| Tax % | 27% | 29% | 27% | 27% | 30% | |
| Net Profit (in Crore INR) |
1,492 | 1,500 | 2,389 | 2,547 | 2,833 | 3,125 |
| EPS in Rs | 18.96 | 19.18 | 29.82 | 31.19 | 34.71 | 38.55 |
| Dividend Payout % | 16% | 21% | 17% | 16% | 24% |
Over the last five years, Cipla has showcased steady growth in its financial performance. The company’s sales have seen a consistent upward trajectory, reaching INR 23,707 crore in the trailing twelve months (TTM) as of March 2023.
Cipla’s operating profit margin (OPM %) has remained resilient, hovering around 23% in the most recent period. The company’s other income has also shown positive trends, contributing to its overall profitability. With efficient cost management, Cipla has continued to generate substantial net profit, totaling INR 3,125 crore in the TTM period.
The earnings per share (EPS) has consistently improved, reaching INR 38.55 in the same timeframe. Additionally, Cipla’s prudent dividend payout policy has ensured shareholder value, with a dividend payout percentage varying between 16% and 24% during this period.
The price-to-earnings ratio (P/E) has fluctuated to 29.3 in July 2023. The company has shown steady growth in revenue and profit, which is reflected in its PAT and EPS.
Overall, Cipla’s financial performance demonstrates a balanced and promising outlook, reflecting its position as a key player in the pharmaceutical industry.
The dividend payout has also increased from 17.12% in March 2018 to 24% in March 2023.
FAQS
It is anticipated that Cipla’s share price will increase to ₹1,783.75 by the end of 2024.
Is it a good time to buy Cipla?
Investors can expect Cipla’s share price to grow in the coming years, making it a solid investment opportunity for those looking to invest in the healthcare sector.
The share price target of Cipla for 2030 might be around ₹5,914.14. With a continued focus on innovation, affordable healthcare solutions, and expanding into new markets, Cipla is well-positioned for continued success in the coming years.
Can CIPLA touch 5000 INR by 2030?
It’s unlikely for Cipla to reach 5000 INR by 2030 based on our price Prediction, as the maximum projected price for 2030 is ₹5,914.14.
The share price target for Cipla in 2025 averages around ₹2,174.64.
Also read:
- KEC International Share Price Target
- TEJAS NETWORKS SHARE PRICE TARGET
- Kotak Mahindra Bank Share Price Target
Conclusion: Charting Cipla’s Course in Healthcare Excellence
Traversing the financial narrative of Cipla unveils a pharmaceutical giant on the brink of substantial growth. With a strategic emphasis on innovation, epitomized by recent breakthroughs like the point-of-care testing device, Cipla emerges as a frontrunner in the dynamic healthcare sector. The resilient Q3 FY24 results underscore global prowess, with North American and South African ventures propelling revenue.
Projected share price targets from 2024 to 2030 indicate an upward trajectory, reflecting investor optimism. Cipla’s steadfast financial performance, marked by burgeoning revenues, judicious cost management, and a commitment to accessible healthcare, cements its standing as a formidable player. As the journey unfolds, Cipla appears well-positioned for enduring success, offering investors a compelling stake in the ever-evolving healthcare landscape.
What did we learn?
